

- 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas.
9. Bazarra-Fernández A. Otra filosofía sobre el cáncer de mama. *Ginecol Obstet Clín.* 2005;6:75-81.
10. Vogel VG, Costantino JP, Wickerham DL, Wolmark N. The effects of tamoxifen versus raloxifene on the risk of developing noninvasive breast cancer in the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. [Abstract 33.] Program and abstracts of the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas.
11. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. *JAMA.* 2006;295:2727-41.
12. Cuzick J, on behalf of the IBIS Investigators. Long term efficacy of tamoxifen for chemoprevention: results of the IBIS-1 study. [Abstract 34.] Program and abstracts of the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas.
13. Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. *JAMA.* 2006;295:2742-51.
14. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. *Cancer J Clin.* 2007;57:43-66.
15. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med.* 2005;353:1784-92.
16. Centers for Disease Control and Prevention (CDC). Use of mammograms among women aged ≥ 40 years —United States, 2000-2005. *MMWR.* 2007;56:49-51.
17. Moss SM. Breast cancer. En: Kramer BS, Gohagan, JK; Prorok, PC, editors. *Cancer screening: Theory and practice.* New York: Marcel Dekker; 1999. p. 149-51.
18. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L; Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: A randomised controlled trial. *Lancet.* 2006;368:2053-60.
19. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: A summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2002;137:347-60.
20. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med.* 2004;351:2817-26.
21. Berrington de González A, Reeves G. Mammographic screening before age 50 years in the UK: Comparison of the radiation risks with the mortality benefits. *Br J Cancer.* 2005;93:590-6.
22. Elmore JG. Ten-year risk of false positive screening mammograms and clinical breast examinations. *N Engl J Med.* 1998;338:1089-96.
23. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. *Lancet.* 2001;358:1340-2.
24. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. *Lancet Oncol.* 2007;8:304-10.